Search

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more

Participation grants & abstract awards

Participation grants
The call for participation grant applications has closed on March 1, 2021 (23:59 CET). Participation grant application has closed

Participation Grants (previously called Travel Grants) provide complimentary registration for the upcoming EHA Virtual Congress.

Read more

EHA and PTHiT Successfully Conclude the Second Joint Virtual Mini Hematology Tutorial

EHA-PTHiT Mini Hematology Tutorial

November 15-16, 2021

Meeting chairs:

Prof G Gaidano (European Hematology Association)
Prof I Hus (Polish Society of Hematology and Transfusion)
Prof T Robak (Polish Society of Hematology and Transfusion) 
After a successful mini Tutorial in April 2021, EHA and PTHiT decided to…

Read more

Secure European Research Funding! Sign the Petition!

 

http://www. no-cuts-on-research. eu
EHA supports European Nobel and Fields Medal prizewinners to prevent the EU research funding for 2014-2020 from being subject to budget cuts.

Read more

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Read more

EHA-Balkan Hematology Day 2025

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 6th edition of the EHA-Balkan Hematology Day.

Read more